Revlimid, Velcade and dexamethasone (also called RVd) are considered to be an optimal treatment for newly diagnosed myeloma. The combination can be used as “induction” therapy prior to transplant or can be used for transplant-ineligible patients.
Daratumumab has been added to this effective regimen for relapsed or refractory myeloma patients with successful results. Now researchers want to know if it can be moved up in the therapy line for newly diagnosed patients. Because there are such strong responses, they want to know if using daratumumab in earlier settings could be beneficial to delay the disease from returning and help patients live longer overall.
Dr. Larry Anderson of the UT Southwestern Medical Center shares more about this open clinical trial in the video below. To learn more about joining this clinical trial that is open at 45 centers, you can find it on SparkCures here:Dara with RVd Clinical Trial